Meropenem API Market Report 2025 (Global Edition)

Global Meropenem API Market Report 2025 Market Size Split by Type (Crude Meropenem, Injection Grade Meropenem), by Application (Bacterial Meningitis, Intra-abdominal infection, Skin and structure Infe...

Meropenem API Market Report Description

We have various report editions of Meropenem API Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Competitive Landscape of the Meropenem API Market

Key players deploy strategic initiatives such as product innovations, partnerships, and mergers. Companies prioritize R&D to introduce innovations, ensuring a competitive edge. 

• In February 2023, Cipla introduced a new generic version of Meropenem to the Indian market. 

Meropenem API Industry News

(Source: https://www.cipla.com/generic-product-list)

• In June 2023, Dr. Reddy's Laboratories Ltd., a worldwide pharmaceutical corporation, announced the opening of its dedicated subsidiary 'RGenX,' which would focus on trading generics in India. Dr. Reddy seeks to expand product offerings and make them more affordable for patients. The new business will help the corporation achieve its aim of reaching over 1.5 billion patients by 2030.

(Sourcehttps://www.drreddys.com/cms/cms/sites/default/files/2023-06/Dr.%20Reddy%27s%20press%20release%20-%20launch%20of%20trade%20generics%20business%20-%2023rd%20June%202023.pdf)

Top Companies Market Share in Meropenem API Industry: (In no particular order of Rank)

• ACS Dobfar
• Savior Lifetec Corporation
• Sumitomo Chemical Company
• Shenzhen Haibin Pharmaceutical
• Zhuhai United Laboratories
• Zhejiang Hisun Pharmaceutical
• Zhejiang Jiuzhou Pharmaceutical
• Sun Pharma
• Kopran
• Hainan Haiyao
• Zhejiang Hisoar
• Kaliberr Labs
• Jeil Pharmaceutical
• Qilu Pharmaceutical
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional analysis of the Meropenem API Market

Which Region will dominate the Meropenem API Market Market in 2024?

According to Cognitive Market Research, North America dominated the market in 2024 and accounted for around 40% of the global revenue. The rising rate of infections acquired in hospitals (HAIs). Infections known as HAIs are contracted by patients while receiving medical care in a hospital. They are a significant issue in North America and are getting more and more resistant to antibiotics. One of the few medicines that is still effective against a variety of HAIs is meropenem.

Which Region is Expanding at the Fastest CAGR?

The Asia Pacific region is witnessing an increase in the morepenem API. This surge is mainly driven by the escalation of antibiotic resistance, the expansion of healthcare consciousness, and the expansion of generic availability. This area is a prominent player in the global market because of its strong API production capabilities, especially in China and India.

The current report Scope analyzes Meropenem API Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Switzerland, Luxembourg, Rest of Europe)
• Asia Pacific (China, Japan, South Korea, India, Australia, Singapore, Taiwan, South East Asia, Rest of APAC)
• Latin America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East (Saudi Arabia, Turkey, UAE, Egypt, Qatar, Rest of Middle East)
• Africa (Nigeria, South Africa, Rest of Africa)

The above graph is for illustrative purposes only.

North America Meropenem API Market Analysis

According to Cognitive Market Research, the global meropenem API market size was estimated at USD XX million, out of which North America held the major market of more than 40% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 2.2% from 2024 to 2031. In North America, meropenem API sales dominate. The elderly population has a higher risk of healthcare-associated infections (HAIs) due to their increased susceptibility to infections and longer hospital admissions. It is anticipated that this tendency would increase North America's demand for meropenem. The injection-grade meropenem in North America is intricately tied to the expanding meropenem API market. Due to its versatility in treating a range of bacterial diseases, such as pneumonia, urinary tract infections, and intra-abdominal infections, injection-grade Meropenem currently holds a dominant market share. For the length of the projection period, this segment is anticipated to stay in the lead.

• According to Cognitive Market Research, the US had a major share in the meropenem APIs market with a market size of USD XX million in 2024 and is projected to grow at a CAGR of 2.0% during the forecast period. Antibiotic resistance is a severe problem in the US, where bacteria such as MRSA are a huge danger. Meropenem is in high demand since it is a broad-spectrum antibiotic that works against some MDR bacteria.
• The Canada meropenem APIs market had a market share of USD XX million in 2024 and is projected to grow at a CAGR of 3.0% during the forecast period. Financial and technical support is extended by the Canadian government to foster the expansion of the pharmaceutical industry, which includes the creation of APIs.
• The Mexico meropenem APIs market is projected to witness growth at a CAGR of 2.7% during the forecast period, with a market size of USD XX million in 2024.

Europe Meropenem API Market Analysis

According to Cognitive Market Research, with a market value of USD XX million in 2024, it is projected to expand at a compound annual growth rate (CAGR) of 2.5% from 2024 to 2031. Europe accounted for a share of over 30% of the global market size of USD XX million. Europe is a force in the sales of intra-abdominal infection; numerous bacteria, such as Escherichia coli, Klebsiella pneumoniae, and Enterococcus faecalis, can result in IAIs. The rising prevalence of IAIs also drives the market for meropenem API. The number of HAIs in Europe is rising, and some of them are resistant to the current round of medicines. The need for the API is fueled by the widespread use of the broad-spectrum carbapenem antibiotic meropenem as a last resort to treat these infections.

• The United Kingdom meropenem APIs market had a market share of USD XX million in 2024 and is projected to grow at a CAGR of 3.3% during the forecast period. The pharmaceutical manufacturing sector in the UK is well-established and strong, with a number of notable corporations such as GlaxoSmithKline (GSK) and
• The France meropenem APIs market is projected to witness growth at a CAGR of 1.7% during the forecast period, with a market size of USD XX million in 2024.
• According to Cognitive Market Research, the Germany meropenem APIs market size was valued at USD XX million in 2024 and is projected to grow at a CAGR of 2.7% during the forecast period. German businesses are renowned for their cutting-edge purification and fermentation techniques, which support the manufacturing of premium meropenem API.
• The Italy meropenem APIs market is projected to witness growth at a CAGR of 1.9% during the forecast period, with a market size of USD XX million in 2024.
• The Russia meropenem APIs market is projected to witness growth at a CAGR of 1.5% during the forecast period, with a market size of USD XX million in 2024.
• The Spain meropenem APIs market is projected to witness growth at a CAGR of 1.6% during the forecast period, with a market size of USD XX million in 2024.
• The Luxembourg meropenem APIs market is projected to witness growth at a CAGR of 2.6% during the forecast period, with a market size of USD XX million in 2024.
• The Portugal meropenem APIs market is projected to witness growth at a CAGR of 2.3% during the forecast period, with a market size of USD XX million in 2024.
• The Greece meropenem APIs market is projected to witness growth at a CAGR of 2.8% during the forecast period, with a market size of USD XX million in 2024.
• The rest of Europe meropenem APIs market is projected to witness growth at a CAGR of 1.2% during the forecast period, with a market size of USD XX million in 2024.

Asia Pacific Meropenem API Market Analysis

According to Cognitive Market Research, the global meropenem API market size was estimated at USD XX million, out of which Asia Pacific held the market of around 23% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 6.0% from 2024 to 2031. The Asia Pacific region is experiencing growth in the meropenem. A greater number of people may now afford Meropenem because of the competitive pricing offered by generic medicine makers in the Asia Pacific. The rising demand for meropenem APIs in the Asia Pacific finds a pivotal ally in the growing preference for injection-grade meropenem as a type. Injection-grade Meropenem, a broad-spectrum antibiotic, is used to treat a wide range of bacterial diseases, including pneumonia, urinary tract infections, and skin infections. It's accessible in both generic and brand-name versions.

• According to Cognitive Market Research, the size of the China meropenem APIs market size was valued at USD XX million in 2024 and is projected to grow at a CAGR of 5.5% during the forecast period. China is home to a sizable and expanding population that is becoming more vulnerable to infectious diseases as a result of urbanization, healthcare inequities, and antibiotic resistance.
• The Japan meropenem APIs market is projected to witness growth at a CAGR of 4.5% during the forecast period, with a market size of USD XX million in 2024.
• The India meropenem APIs market had a market share of USD XX million in 2024 and is projected to grow at a CAGR of 7.8% during the forecast period. The demand for Meropenem is being further stimulated by the government of India's initiatives to increase awareness of antimicrobial resistance and encourage the prudent use of antibiotics.
• The South Korea meropenem APIs market is projected to witness growth at a CAGR of 5.1% during the forecast period, with a market size of USD XX million in 2024.
• The Australia meropenem APIs market is projected to witness growth at a CAGR of 5.7% during the forecast period, with a market size of USD XX million in 2024.
• The South East Asia meropenem APIs market is projected to witness growth at a CAGR of 7.0% during the forecast period, with a market size of USD XX million in 2024.
• The Rest of the Asia Pacific meropenem APIs market is projected to witness growth at a CAGR of 5.8% during the forecast period, with a market size of USD XX million in 2024.

South America Meropenem API Market Analysis

According to Cognitive Market Research, the global meropenem APIs market size was estimated at USD XX million, out of which the Latin America market has more than 5% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 3.4% from 2024 to 2031. Meropenem API sales in Latin America are experiencing growth due to the usage of broad-spectrum antibiotics like meropenem, which is rising as a result of increased awareness of the threat posed by antimicrobial resistance. The upswing in injection-grade meropenem across Latin America is closely tied to the expanding meropenem API market. In Latin America, injection-grade meropenem is the most widely accessible kind. It is used to treat a range of dangerous bacterial infections, such as skin and soft tissue infections, urinary tract infections, and pneumonia, and is given intravenously.

• According to Cognitive Market Research, the Brazil meropenem APIs market size was valued at USD XX million in 2024 and is projected to grow at a CAGR of 4.0% during the forecast period. In Brazil, HAIs are a serious issue that causes an estimated 37,000 fatalities annually. The broad-spectrum antibiotic meropenem works well against a variety of bacteria, including those that cause health-associated infections (HAIs).
• The Argentina meropenem APIs market had a market share of USD XX million in 2024 and is projected to grow at a CAGR of 4.3% during the forecast period. As the primary source of illness and mortality in Argentina, HAIs represent a significant issue. The demand for Meropenem API is being driven by the rising incidence of healthcare-associated infections (HAIs), as the antibiotic is broad-spectrum and effective against a variety of bacteria.
• The Colombia meropenem APIs market is projected to witness growth at a CAGR of 3.2% during the forecast period, with a market size of USD XX million in 2024.
• The Peru meropenem APIs market is projected to witness growth at a CAGR of 3.6% during the forecast period, with a market size of USD XX million in 2024.
• The Chile meropenem APIs market is projected to witness growth at a CAGR of 3.7% during the forecast period, with a market size of USD XX million in 2024.
• The Rest of Latin America, meropenem APIs market is projected to witness growth at a CAGR of 2.5% during the forecast period, with a market size of USD XX million in 2024.

Middle East Meropenem API Market Analysis

According to Cognitive Market Research, the global meropenem API market size was estimated at USD XX million, out of which the Middle East and Africa held the major market of around 2% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 3.7% from 2024 to 2031. MEA experiences an upswing in meropenem API sales driven by There's a rising need for novel and creative antibiotic therapies as HAIs become more common. An extensive spectrum of bacteria can be effectively combated by the broad-spectrum antibiotic meropenem, including ones that are resistant to other medications. The rise of injection-grade meropenem in the MEA region aligns with the flourishing meropenem API market. Injection Grade Meropenem is the most prevalent type of Meropenem available on the market. It is a sterile, white powder that is diluted with water before being injected intravenously. Meropenem, injection grade, is used to treat a variety of bacterial infections, including pneumonia, urinary tract infections, and skin and soft tissue infections.

• According to Cognitive Market Research, the GCC countries meropenem APIs market size was valued at USD XX million in 2024 and is projected to grow at a CAGR of 4.5% during the forecast period. Governments in the GCC region are investing considerably in healthcare, which is driving up demand for drugs like Meropenem.
• The Egypt meropenem APIs market is projected to witness growth at a CAGR of 4.0% during the forecast period, with a market size of USD XX million in 2024.
• The South Africa meropenem APIs market is projected to witness growth at a CAGR of 4.7% during the forecast period, with a market size of USD XX million in 2024. In South Africa, infectious disorders such as pneumonia, meningitis, and urinary tract infections are becoming more prevalent.
• The Turkey meropenem APIs market is projected to witness growth at a CAGR of 3.2% during the forecast period, with a market size of USD XX million in 2024.
• The Nigeria meropenem APIs market is projected to witness growth at a CAGR of 2.8% during the forecast period, with a market size of USD XX million in 2024.
• The Rest of the MEA meropenem APIs market is projected to witness growth at a CAGR of 2.7% during the forecast period, with a market size of USD XX million in 2024.

Meropenem API Market Analysis

Meropenem API Market Type Segment Analysis

According to Cognitive Market Research, injection-grade meropenem held the major market share over the forecast period. Meropenem for injectable grade is a non-pyrogenic, sterile powder that needs to be reconstituted with sterile water before use. It comes in several dosages and container sizes. Prominent producers of injection-grade meropenem comprise Sun Pharmaceutical Industries, Fresenius Kabi, and Pfizer.

Crude meropenem is the fastest-growing category over the forecast period. An intermediate product used in the production of meropenem API is crude meropenem. It is made by fermenting a strain of Streptomyces hygroscopicus bacteria. After that, raw meropenem is refined and processed to create meropenem API.

• Crude Meropenem
• Injection Grade Meropenem

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Meropenem API Industry. Request a Free Sample PDF!

Meropenem API Market Application Segment Analysis

According to Cognitive Market Research, Intra-abdominal infection holds a prominent market share. Infections within the abdomen (IAIs) are a leading global cause of morbidity and mortality. Among the causes of IAIs is the increased use of medical gadgets, which can increase the risk of IAIs with the use of medical equipment such as feeding tubes and catheters. IAIs can result from germs introduced into the abdomen after surgery, and chronic conditions, including diabetes and inflammatory bowel disease, can also raise the risk of IAIs.

Bacterial meningitis is the fastest-growing category over the forecast period. A broad-spectrum carbapenem antibiotic called meropenem is prescribed to treat a variety of bacterial diseases, including bacterial meningitis brought on by bacterial strains that are sensitive to therapy. Because of its efficacy against MDR bacteria, it is frequently utilized as a last-resort treatment for cases of meningitis that are resistant to other antibiotics.

• Bacterial Meningitis
• Intra-abdominal infection
• Skin and structure Infection
• Others

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Meropenem API Route of Administration Segment Analysis

According to Cognitive Market Research, Intravenous injection holds a prominent market share. Meropenem's excellent absorption and quick onset of effect make intravenous injection the recommended method of administration. The growing geriatric population, which is more prone to infections, the increasing frequency of severe infections that necessitate systemic antibiotic therapy, and the growing number of surgical procedures, which can raise the risk of infection, are the factors driving the intravenous injection market for meropenem.

Intramuscular injection is the fastest-growing category over the forecast period. The rising demand for self-administration of drugs and home healthcare is driving the market for intramuscular injections. Intramuscular injections are also the ideal method when administering drugs that must be administered fast, or that are not well absorbed orally.

• Intravenous Injection
• Intramuscular Injection

Author's Detail

Ashwini Moharir

Research Analyst at Cognitive Market Research

LinkedIn

Profile

Enthusiastic and analytical market research professional with 2 years of hands-on experience in tracking market trends, evaluating consumer behavior, and supporting strategic decision-making. Proficient in designing surveys, conducting interviews, and synthesizing insights from both primary and secondary sources. Successfully contributed to research projects across sectors such as retail, personal care, and industrial markets. Brings a keen eye for detail, strong data interpretation skills, and a passion for uncovering what drives markets forward. Comfortable working in fast-paced environments and collaborating across departments to deliver clear, actionable findings.

Author's Conclusion